Cargando…

A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis

BACKGROUND: Ulcerative colitis (UC) is characterized by refractory and recurrent mucosal inflammation, leading to a substantial healthcare burden. Diagnostic biomarkers predicting disease activity and treatment response remain elusive. To evaluate the application value of a novel neutrophil-based in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhou, Zhang, Yinghui, Pan, Yan, Yang, Xue, Li, Liangping, Gao, Caiping, He, Chong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092064/ https://www.ncbi.nlm.nih.gov/pubmed/35572985 http://dx.doi.org/10.3389/fmed.2022.872831

Ejemplares similares

Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
por: Zhou, Zhou, et al.
Publicado: (2022)

Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis
por: Huang, Xijing, et al.
Publicado: (2023)

Clinical Utility of the Neutrophil-to-Bilirubin Ratio in the Detection of Disease Activity in Ulcerative Colitis
por: Huang, Xijing, et al.
Publicado: (2023)

Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis
por: Nishida, Yu, et al.
Publicado: (2017)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
por: Gordon, Benjamin L., et al.
Publicado: (2023)

Novel Gene Signatures Predicting Primary Non-response to Infliximab in Ulcerative Colitis: Development and Validation Combining Random Forest With Artificial Neural Network
por: Feng, Jing, et al.
Publicado: (2021)

Editorial: Recent advances and new biomarkers in ulcerative colitis
por: Velikova, Tsvetelina, et al.
Publicado: (2023)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
por: Seo, Hyun Il, et al.
Publicado: (2014)

Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
por: Puthoor, Pamela R., et al.
Publicado: (2013)

Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series
por: Markovic, Srdjan, et al.
Publicado: (2021)

Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis
por: Lyu, Xue, et al.
Publicado: (2023)

Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis
por: Szemes, Kata, et al.
Publicado: (2020)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
por: Adibi, Peyman, et al.
Publicado: (2011)

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
por: Lawlor, Garrett, et al.
Publicado: (2009)

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis
por: Mirza, Muhammad, et al.
Publicado: (2018)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
por: deBruyn, Jennifer C. C., et al.
Publicado: (2021)

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
por: Keil, Radan, et al.
Publicado: (2016)

Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis
por: Jia, Xuemei, et al.
Publicado: (2020)

Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis
por: Liu, Lu, et al.
Publicado: (2022)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis
por: Tsuchiya, Atsunori, et al.
Publicado: (2018)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
por: Warpechowski, Marcin, et al.
Publicado: (2023)

Pediatric ulcerative colitis: current treatment approaches including role of infliximab
por: Bradley, Gia M, et al.
Publicado: (2012)

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
por: Chaudhary, Mohammad A., et al.
Publicado: (2012)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Disseminated Nocardiosis Associated with Treatment with Infliximab in a Patient with Ulcerative Colitis
por: Garner, Orlando, et al.
Publicado: (2017)

Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
por: Liu, Yi-Juan, et al.
Publicado: (2018)

Sarcoidosis associated with infliximab therapy in ulcerative colitis: A case report
por: Gîlcă, Georgiana-Emmanuela, et al.
Publicado: (2017)

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
por: Viscido, Angelo, et al.
Publicado: (2019)

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
por: Berends, Sophie E., et al.
Publicado: (2019)

Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report
por: Huang, Bin-Bin, et al.
Publicado: (2020)

De novo ulcerative colitis after kidney transplantation treated with infliximab
por: Oki, Rikako, et al.
Publicado: (2021)

Ramsay Hunt Syndrome in a Patient with Ulcerative Colitis Treated with Infliximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tu9g6pjlocd3rj5p57jk6c3p0r